Devyser Diagnostics AB publishes quarterly report for the period April to June 2024
“Devyser continued to report high sales growth in the second quarter. Organic growth compared with...
Fetal RHD screening NIPT | October 13, 2022
Early non-invasive prenatal testing (NIPT) for fetal Rhesus D (RHD) status is playing an increasingly prominent role in antenatal care to ensure that anti-D prophylaxis is targeted to those women who will benefit from it. Devyser RHD is a CE-IVD test kit that uses cell free fetal DNA from maternal plasma to determine RhD blood group incompatibility as early as gestation week 10. With 99.9% diagnostic sensitivity and 99.9%specificity, our unique single-exon assay enables labs to increase throughput and shorten turnaround times. Devyser RHD builds on published methods for PCR based detection of exon 4 of the RHD gene, which encodes the Rh Blood Group D Antigen. Our kit improves on published sensitivity and specificity values for this test, and provides a simplified assay design that helps streamline and standardize the testing workflow.
We have summarized the findings of three seminal publications that support clinical implementation of our well-established single-exon detection strategy for fetal RHD screening in the first trimester of pregnancy to guide targeting of routine antenatal anti-D prophylaxis (RAADP).
What you'll learn
Learn why these studies are important and understand the key findings and conclusions:
• High sensitivity and specificity
• Good window of stability for routine clinical use
• High accuracy using exon 4 only, regardless of PCR strategy
• Very low false negative and low false positive rates
• Potential to reduce unnecessary anti-D treatment
Preview
Devyser RHD builds on published methods for PCR based detection of exon 4 of the RHD gene, which encodes the Rh Blood Group D Antigen. Our kit improves on published sensitivity and specificity values for this test, and provides a simplified assay design that helps streamline and standardize the testing workflow. Here we summarize the findings of three seminal publications that support clinical implementation of this well-established single-exon detection strategy for fetal RHD screening in the first trimester of pregnancy to guide targeting of routine antenatal anti-D prophylaxis (RAADP).
